Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease which predisposes to life-threatening ventricular arrhythmias. The main goal of ARVC therapy is prevention of sudden cardiac death (SCD). Implantable cardioverter defibrillator (ICD) is the most effective therapy for interruption of potentially lethal ventricular tachyarrhythmias. Despite its life-saving potential, ICD implantation is associated with a high rate of complications and significant impact on quality of life. Accurate risk stratification is needed to identify individuals who most benefit from the therapy. While there is general agreement that patients with a history of cardiac arrest or hemodynamically unstable ventricular tachycardia are at high risk of SCD and needs an ICD, indications for primary prevention remain a matter of debate. The article reviews the available scientific evidence and guidelines that may help to stratify the arrhythmic risk of ARVC patients and guide ICD implantation. Other therapeutic strategies, either alternative or additional to ICD, will be also addressed.
['Zorzi|Alessandro|A|', 'Rigato|Ilaria|I|', 'Bauce|Barbara|B|', 'Pilichou|Kalliopi|K|', 'Basso|Cristina|C|', 'Thiene|Gaetano|G|', 'Iliceto|Sabino|S|', 'Corrado|Domenico|D|']
D019571:Arrhythmogenic Right Ventricular Dysplasia D016757:Death, Sudden, Cardiac D017147:Defibrillators, Implantable D006801:Humans D018570:Risk Assessment D012307:Risk Factors D016019:Survival Analysis
Ventricular arrhythmias Sudden cardiac death Implantable cardioverter defibrillator Ventricular tachycardia Guidelines Ventricular fibrillation